| |
|
|
|
Summit Therapeutics Inc.  
|
|
5.63 -0.04 (-0.01%) |
03-08 15:59 |
|
Open: |
5.67 |
Pre close: |
5.67 |
Target:
|
11.13
|
|
High: |
5.94 |
Low: |
5.61 |
Resistance:
|
9.53
12.30
|
|
Volume: |
202,077 |
Market Cap: |
465M |
Support:
|
5.04
4.19
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
5.88
 |
MACD |
MACD(12,26):
|
-0.29 |
|
MA(20): |
7.31 |
Signal(12,26,9): |
-0.01 |
|
MA(100): |
5.36  |
Stochastic Oscillator |
%K(14,3):
|
14.60 |
|
MA(250): |
4.15 |
%D(3): |
9.25 |
|
Average Volume(K) |
3-Month: |
26182
|
52-Week |
High:
|
12.30 |
|
10-Days: |
18059 |
Low: |
1.65 |
|
RSI |
RSI(14):
|
38.87 |
Change(%): |
233.2 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.260 |
Return on Equity (ttm) |
0.0 |
Shares Out. (M) |
82.58 |
|
EPS Est. Current Year |
-0.530 |
Return on Assets (ttm) |
0.0 |
Shares Float (M) |
21.64 |
|
EPS Est. Next Year |
-1.050 |
PEG Ratio |
0.00 |
% Held by Insiders |
73.57 |
|
EPS Est. Next Quarter |
-0.620 |
Qtrly Rev. Growth |
22.3 |
% Held by Institutions |
10.54 |
|
Forward EPS |
0.118 |
Gross Profit (p.s.) |
0.208 |
Shares Short (K) |
290 |
|
Book Value (p.s.) |
0.550 |
EBITDA (p.s.) |
-0.656 |
P/E |
-21.79 |
|
Sales Per Share |
0.267 |
Qtrly Earnings Growth |
0.00 |
P/BV |
10.30 |
|
Profit Margin |
-227.63 |
Operating Cash Flow
(M) |
-48.38 |
P/S |
21.18 |
|
Operating Margin |
-247.56 |
Levered Free Cash Flow
(M) |
0.00 |
P/CF |
-9.67 |
|
|
|
|
|
|
